MedTrace Logo

Optimizing Microdosing and Meditation

NCT06560658 · Status: WITHDRAWN · Phase: NA · Type: INTERVENTIONAL

Last updated 2025-06-05

No results posted yet for this study

Summary

The goal of this clinical trial is to test the feasibility of combining meditation with psilocybin microdosing in healthy adults. The main questions it aims to answer are:

1. Recruitment and retention feasibility
2. Acceptability, Safety and Tolerability
3. Exploratory Measures:

3.1: Explore potential changes in sleep quality and duration, heart rate variability, and other biometric outcomes captured by the Oura Ring (3rd generation).

3.2: Explore potential changes in quality of life scores 3.3: Explore potential differences in altered states of consciousness across groups 3.4: Explore qualitative data collected during sessions and at follow-up to assess satisfaction and receive feedback about the intervention.

Every participant will receive the psilocybin microdosing intervention, however, half of the participants will be randomly selected to receive the meditation intervention.

Conditions

  • Meditation
  • Microdosing

Interventions

DRUG

Psilocybin

Participants will receive four 2-hour sessions of supervised microdosing of psilocybin in a two week period.

BEHAVIORAL

Meditation

Participants will receive four 2-hour sessions of supervised microdosing of psilocybin in a two week period. In addition to meditating during their sessions, participants will also meet online five days a week for meditation instruction and practice.

Sponsors & Collaborators

  • National University of Natural Medicine

    lead OTHER

Principal Investigators

  • Matthew Hicks, ND, MS · National University of Natural Medicine

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
21 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2024-10-01
Primary Completion
2025-10-01
Completion
2025-11-01

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06560658 on ClinicalTrials.gov